PTM SEMA

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Ulcerative ColitisHIV InfectionCirrhosisHIV

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

1

Jyseleca

Gilead

Phase 3

62

Icotyde

Johnson & Johnson

Phase 3

—3

ABX464

AAbivax S.A.

Phase 3

84

PTM SEMA

Gilead

Phase 3

15

Ontamalimab

Takeda

Phase 3

46

RPC1063

Bristol-Myers Squibb

Phase 3

27

Etrolizumab

Roche

Phase 3

78

Simponi

Johnson & Johnson

Preclinical

159

CT-P13 SC (infliximab)

CCelltrion

Phase 3

110

Remicade

OOrganon and Co

Preclinical

26Show 26 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Ulcerative Colitis1 trial

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis

Completed·Gilead·Phase 3·NCT02914522·1,351 enrolled

HIV infection1 trial

Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection

Active, not recruiting·Gilead·Phase 3·NCT04994509·5,368 enrolled

Tenofovir1 trial

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

Active, not recruiting·Gilead·Phase 3·NCT06630286·609 enrolled

Cirrhosis1 trial

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Completed·Gilead·Phase 2·NCT04971785·457 enrolled

HIV1 trial

PURPOSE-1: Lenacapavir PrEP for HIV Prevention

Completed·Gilead·Phase 3·NCT04925752·5,338 enrolled

Details

Drug Info

Related News